These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26903519)

  • 1. Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
    Healy MA; Yin H; Reddy RM; Wong SL
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26903519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma.
    Yasuda T; Higuchi I; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Hatazawa J; Doki Y
    Ann Surg Oncol; 2012 Feb; 19(2):652-60. PubMed ID: 21769466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
    Torrance AD; Almond LM; Fry J; Wadley MS; Lyburn ID
    Surgeon; 2015 Feb; 13(1):19-33. PubMed ID: 24206935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: results from a population-based study.
    Wani S; Das A; Rastogi A; Drahos J; Ricker W; Parsons R; Bansal A; Yen R; Hosford L; Jankowski M; Sharma P; Cook MB
    Cancer; 2015 Jan; 121(2):194-201. PubMed ID: 25236485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.
    Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
    Radiology; 2013 Jun; 267(3):807-17. PubMed ID: 23418003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.
    Marcus C; Paidpally V; Antoniou A; Zaheer A; Wahl RL; Subramaniam RM
    J Nucl Med; 2015 Feb; 56(2):204-8. PubMed ID: 25613535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
    You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
    J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET and PET-CT in esophageal and gastric cancer.
    Wieder HA; Krause BJ; Herrmann K
    Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
    Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
    Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.